Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Small Cell Lung Carcinoma 1Neurofibromatosis 2 1Neoplasms 1Neoplasm Metastasis 1Meningioma 1DLBCL 1Carcinoma, Non-Small-Cell Lung 1Advanced Metastatic Breast Cancer 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms × vistusertib × Clear all
NCT01026402 2016-02-11

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

AstraZeneca

Phase 1 Completed
172 enrolled 35 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡